In Depth Research on US Breast Cancer Drug Market Outlook 2022

“US Breast Cancer Drug Market Outlook 2022” Report Highlights:

* US Breast Cancer Tendencies
* US Breast Cancer Drug Market Outline
* US Breast Cancer Drug Market Dynamics
* Breast Cancer Risk Undercurrents
* US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis
* US Breast Cancer Marketed Drugs Clinical Insight: 18 Drugs

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-US-Breast-Cancer-Drug-Market-Outlook-2022.php

Table of contents

1. US Cancer Prevalence Rate
1.1 Overview
1.2 Glimpse of Past Cancer Incidences
1.3 Current Drifts in Cancer Frequencies
1.4 Estimated Future Cancer Occurrences

2. US Breast Cancer Tendencies
2.1 Indication
2.2 Breast Cancer Historical Incidences
2.3 Recent inclinations in Breast Cancer
2.4 Breast Cancer Frequencies over Age & Race

3. Breast Cancer Risk Undercurrents
3.1 Hormonal Aspects
3.2 Family History & Genetic Predisposition
3.3 Cumulative Age & Elevated Risk
3.4 Management of Breast Cancer

4. US Breast Cancer Drug Market Outline
4.1 Topographical Arcade Sales
4.2 HER-2 Positive Drug Market

5. US Breast Cancer Drug Market Dynamics
5.1 Breast Cancer Market Accelerative Parameters
5.2 Breast Cancer Market Challenges

6. US Breast Cancer Drug Market Future Aspects

US Breast Cancer Marketed Drugs Clinical Insight by Company & Patent Analysis

7. Eribulin (Halaven)
7.1 Clinical Introduction
7.2 Brand Names
7.3 Recording & Reporting Of Clinical Adverse Events

8. Trastuzumab Emtansine (Kadcyla)
8.1 Clinical Introduction
8.2 Brand Names
8.3 Recording & Reporting Of Clinical Adverse Events

9. Palbociclib (Ibrance)
9.1 Clinical Introduction
9.2 Brand Names
9.3 Recording & Reporting Of Clinical Adverse Events

10. Pertuzumab (Omnitarg & Perjeta)
10.1 Clinical Introduction
10.2 Brand Names
10.3 Recording & Reporting Of Clinical Adverse Events

11. Gadobutrol (Gadavist, Gadovist & Gadovist 1.0)
11.1 Clinical Introduction
11.2 Brand Names
11.3 Recording & Reporting Of Clinical Adverse Events

12. Lapatinib (Tykerb)
12.1 Clinical Introduction
12.2 Brand Names
12.3 Recording & Reporting Of Clinical Adverse Events

13. Tamoxifen Oral Liquid (Soltamox)
13.1 Clinical Introduction
13.2 Brand Names
13.3 Recording & Reporting Of Clinical Adverse Events

14. Fulvestrant (Faslodex)
14.1 Clinical Introduction
14.2 Brand Names
14.3 Recording & Reporting Of Clinical Adverse Events

15. Anastrozole (Arimidex)
15.1 Clinical Introduction
15.2 Brand Names
15.3 Recording & Reporting Of Clinical Adverse Events

16. Ixabepilone (Ixempra)
16.1 Clinical Introduction
16.2 Brand Names
16.3 Recording & Reporting Of Clinical Adverse Events

17. Toremifene (Fareston)
17.1 Clinical Introduction
17.2 Brand Names
17.3 Recording & Reporting Of Clinical Adverse Events

18. Letrozole (Femara)
18.1 Clinical Introduction
18.2 Brand Names
18.3 Recording & Reporting Of Clinical Adverse Events

19. Raloxifene (Celvista, Evista, Optruma & Sevista (raloxifene))
19.1 Clinical Introduction
19.2 Brand Names

20. Exemestane (Aromasin)
20.1 Clinical Introduction
20.2 Brand Names
20.3 Recording & Reporting Of Clinical Adverse Events

21. Vitamin B12 Fluorescent-Analogues (CobalaFluor Green & CobalaFluor Red)
21.1 Clinical Introduction
21.2 Brand Names

22. Trastuzumab Companion Diagnostic (HER2 CISH pharmDx)
22.1 Clinical Introduction
22.2 Brand Names

23. Fluoxymesterone
23.1 Clinical Introduction
23.2 Recording & Reporting Of Clinical Adverse Events

24. Competitive Landscape
24.1 Agilent Technologies
24.2 AstraZeneca
24.3 Bayer HealthCare Pharmaceuticals
24.4 Bristol-Myers Squibb
24.5 Eisai Co Ltd
24.6 Eli Lilly
24.7 Novartis
24.8 Onyx Pharmaceuticals
24.9 Orion
24.10 Perrigo
24.11 Pfizer
24.12 Roche

Figure 1-1: Top Ten Countries in Cancer Incidence Trends
Figure 1-2: Global - Reported Deaths for the Leading Cancers in Men, 2012
Figure 1-3: US - Estimated Number of New Cancer Cases by Sex, 2016
Figure 2-1: Relationship between Age & Breast Cancer
Figure 2-2: Prevalence of Female Breast Cancer According to Ethnicity
Figure 3-1: Various Risk Factors Associated With Breast Cancer
Figure 4-1: Estimated Breast Cancer Deaths in North East Of US, 2016
Figure 4-2: HER-2 Positive Receptor & Herceptin
Figure 5-1: Accelerative Parameters of Breast Cancer Market
Figure 5-2: Current Challenges in Breast Cancer Therapeutics
Figure 8-1: Kadcyla - US Sales (Million US$), 2013-2022
Figure 8-2: Kadcyla - Global Sales (Million US$), 2013-2022
Figure 9-1: Ibrance - US Sales (Million US$), 2015-2022
Figure 9-2: Ibrance - Global Sales (Million US$), 2015-2022
Figure 10-1: Omnitarg- US Sales (Million US$), 2015-2022
Figure 10-2: Omnitarg / Perjeta - Global Sales (Million US$), 2015-2022
Figure 11-1: Gadavist - US Sales (Million US$), 2015-2022
Figure 11-2: Gadavist - Global Sales (Million US$), 2015-2022
Figure 12-1: Tykerb - US Sales (Million US$), 2015-2022
Figure 12-2: Tykerb - Global Sales (Million US$), 2015-2022
Figure 15-1: Arimidex - US Sales (Million US$), 2015-2022
Figure 15-2: Arimidex - Global Sales (Million US$), 2015-2022
Figure 16-1: Ixempra - US Sales (Million US$), 2015-2022
Figure 16-2: Ixempra - Global Sales (Million US$), 2015-2022
Figure 18-1: Femara - US Sales (Million US$), 2015-2022
Figure 18-2: Femara - Global Sales (Million US$), 2015-2022
Figure 24-1: Novartis - Clinical Pipeline
Figure 24-2: Roche - Clinical Pipeline

Table 1-1: US - Estimated Number* of New Cancer Cases and Deaths by Sex, 2016
Table 1-2: US - Estimated Number* of New Cases for Selected Cancers by State, 2016
Table 1-3: US - Estimated Number* of Deaths for Selected Cancers by State, 2016

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
India
+91-11-47067990

This release was published on openPR.